| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $0 worth of Foghorn Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $1.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.
| 2024-09-23 | Sale | Costa Carlos | Chief People Officer | 857 0.0017% | $10.17 | $8,716 | -47.00% | |
| 2024-09-20 | Sale | Costa Carlos | Chief People Officer | 35,756 0.0649% | $10.04 | $358,990 | -50.65% | |
| 2024-09-18 | Sale | Costa Carlos | Chief People Officer | 11,574 0.022% | $10.05 | $116,319 | -48.33% | |
| 2024-09-17 | Sale | Costa Carlos | Chief People Officer | 10,272 0.0189% | $10.04 | $103,131 | -49.80% | |
| 2024-09-16 | Sale | Costa Carlos | Chief People Officer | 400 0.0008% | $10.00 | $4,000 | -46.38% | |
| 2024-09-09 | Sale | Bellon Steven F. | Chief Scientific Officer | 20,000 0.0366% | $9.50 | $190,000 | -46.85% | |
| 2024-03-11 | Sale | Cavalie Fanny | Chief Strategy/Bus Ops Officer | 11,000 0.0249% | $6.56 | $72,134 | -11.01% | |
| 2023-08-16 | Sale | Agresta Samuel | Chief Medical Officer | 311,297 0.6823% | $8.25 | $2.57M | -35.56% | |
| 2020-10-27 | Flagship Ventures Fund V General Partner LLC | 10 percent owner | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | ||
| 2020-10-27 | Abu Dhabi Investment Authority | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | |||
| 2020-10-27 | DECICCO CARL | Chief Scientific Officer | 5,500 0.0498% | $16.00 | $88,000 | -20.50% |
| Flagship Ventures Fund V General Partner LLC | 10 percent owner | 9330878 15.928% | $52.91M | 1 | 0 | <0.0001% |
| Abu Dhabi Investment Authority | 1231081 2.1015% | $6.98M | 1 | 0 | <0.0001% | |
| DECICCO CARL | Chief Scientific Officer | 258397 0.4411% | $1.47M | 1 | 0 | <0.0001% |
| Bellon Steven F. | Chief Scientific Officer | 101957 0.174% | $578,096.19 | 0 | 1 | |
| Cavalie Fanny | Chief Strategy/Bus Ops Officer | 75992 0.1297% | $430,874.64 | 0 | 1 | |
| Agresta Samuel | Chief Medical Officer | 0 0% | $0 | 0 | 1 | |
| Costa Carlos | Chief People Officer | 0 0% | $0 | 0 | 5 |
$26,922,905 | 100 | 5.55% | $313.89M | |
$5,960,789 | 91 | -7.17% | $374.07M | |
$69,151,774 | 71 | 24.96% | $327.53M | |
$5,911,307 | 70 | -1.38% | $351.73M | |
$87,639,490 | 62 | 18.37% | $312.55M | |
$24,384,691 | 42 | -30.27% | $376.86M | |
$64,487,106 | 32 | -22.92% | $330.92M | |
$54,828,550 | 26 | -13.88% | $331.71M | |
$1,842,003 | 22 | -0.74% | $349.8M | |
$1,447,973 | 17 | 13.95% | $300.73M | |
$110,580 | 16 | 14.52% | $316.63M | |
$10,143,329 | 12 | 11.84% | $357.77M | |
$13,043,783 | 8 | 732.82% | $330.19M | |
$17,675,244 | 7 | 92.20% | $322.5M | |
$12,035,408 | 5 | -37.54% | $370.82M | |
$184,294 | 3 | -10.64% | $389.07M | |
$2,720,023 | 3 | -11.76% | $370.36M | |
Foghorn Therapeutics Inc. (FHTX) | $4,888,000 | 3 | -20.50% | $332.16M |
$20,020,000 | 1 | -75.24% | $388.43M |
| Increased Positions | 46 | +52.87% | 2M | +5.71% |
| Decreased Positions | 32 | -36.78% | 828,345 | -2.05% |
| New Positions | 15 | New | 817,618 | New |
| Sold Out Positions | 9 | Sold Out | 223,298 | Sold Out |
| Total Postitions | 101 | +16.09% | 42M | +3.66% |
| Flagship Pioneering Inc. | $65,779.00 | 22.24% | 12.67M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $28,413.00 | 9.6% | 5.47M | -60,025 | -1.08% | 2025-09-30 |
| Bvf Inc/Il | $27,517.00 | 9.3% | 5.3M | 0 | 0% | 2025-09-30 |
| Deerfield Management Company, L.P. | $16,896.00 | 5.71% | 3.26M | 0 | 0% | 2025-09-30 |
| Raymond James Financial Inc | $12,780.00 | 4.32% | 2.46M | +95,196 | +4.02% | 2025-09-30 |
| Blackrock, Inc. | $11,729.00 | 3.97% | 2.26M | +30,815 | +1.38% | 2025-09-30 |
| Vanguard Group Inc | $9,858.00 | 3.33% | 1.9M | +14,784 | +0.78% | 2025-09-30 |
| Euclidean Capital Llc | $8,168.00 | 2.76% | 1.57M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $4,196.00 | 1.42% | 808,488 | +814 | +0.1% | 2025-09-30 |
| Siren, L.L.C. | $3,741.00 | 1.26% | 720,720 | 0 | 0% | 2025-09-30 |